Rationale and content of psychenet: the Hamburg Network for Mental Health
- 471 Downloads
With the public-funded research and development project psychenet: the Hamburg Network for Mental Health (2011–2014), the Federal Ministry of Education and Research contributes to strengthening healthcare regions in Germany by establishing new trans-sectoral cooperations and implement and evaluate selected innovations. More than 60 partners from research, health care, health industry and government in the Free and Hanseatic City of Hamburg are promoting innovative measures to improve the treatment for mental disorders. The main objective is to implement integrated healthcare networks based on evidence for effective treatment methods, deriving from high-quality research throughout five indications such as psychosis, depression, somatoform and functional syndromes, anorexia and bulimia and addiction illnesses in adolescence. Those networks are accompanied by additional measures, for example, for improving information and education, addressing occupational health or strengthening the participation of patients and their families suffering from mental illness.
KeywordsMental health Integrated health care Evidence-based medicine Guidelines Complex interventions
“psychenet: Hamburg Network for Mental Health” is a project funded by the Federal Ministry for Education and Research (BMBF) from 2011 to 2014, with which the City of Hamburg was given the title “Health Region of the Future” in 2010. The aim of the project is to promote mental health today and in the future, and to achieve an early diagnosis of and effective treatment for mental illnesses. Further information and a list of all project partners can be found at www.psychenet.de.
Conflict of interest
Martin Lambert has received grant/research support from AstraZeneca and Janssen-Cilag, and honoraria from AstraZeneca, EliLilly, Janssen-Cilag and Bristol-Myers Squibb and has served on speakers boards for AstraZeneca, Janssen-Cilag and Eli Lilly. Anne Karow has received grant/research support from Bristol-Myers Squibb and Eli Lilly and has served on speaker boards for AstraZeneca, Bristol-Myers Squibb, Janssen-Cilag, Eli Lilly and Pfizer. The other authors declare that they have no conflict of interest. This article is part of the supplement “Personalized Psychiatry and Psychotherapy“. This supplement was not sponsored by outside commercial interests. It was funded by the German Association for Psychiatry and Psychotherapy (DGPPN).
- 2.Deutsche Rentenversicherung Bund (2010) Reha-Bericht 2010 (online http://www.deutsche-renten-versicherung-bund.de/cae/servlet/contentblob/89894/publication-File/17732/rehabericht_2010.pdf
- 5.Härter M, Klesse C, Bermejo I, Schneider F, Berger M (2010) Unipolare Depression—Empfehlungen zur Diagnostik und Therapie aus der aktuellen S3- und Nationalen VersorgungsLeitlinie “Unipolare Depression”. Deutsch Ärztebl Int 107(40):700–708Google Scholar